enGene Therapeutics Inc. Common Stock

ENGNNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
1.64 USD
↘ 0.08 (4.65%)AT CLOSE (11:59 AM EDT)
1.62
↘ 0.02 (1.22%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
1.62
↘ 0.02 (1.22%)
🔴Market: CLOSED
Open?$1.71
High?$1.74
Low?$1.61
Prev. Close?$1.72
Volume?954.4K
Avg. Volume?2.9M
VWAP?$1.65
Rel. Volume?0.33x
Bid / Ask
Bid?$1.61 × 2.0K
Ask?$1.67 × 900
Spread?$0.06
Midpoint?$1.64
Valuation & Ratios
Market Cap?109.9M
Shares Out?N/A
Float?50.2M
Float %?74.9%
P/E Ratio?N/A
P/B Ratio?0.39
EPS?-$1.83
Dividend?0.00%
Ex-Dividend?N/A

enGene Therapeutics Inc. Common Stock (ENGN) is currently trading at $1.64. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingHealthcare - Oncology›Cell & Gene Therapy for Cancer
Employees
82
Market Cap
109.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.engene.com
Listed
2023-11-01
Address
4868 RUE LEVY, SUITE 220
SAINT-LAURENT, A8 H4R 2P1
Phone: (514) 332-4888
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
1
Momentum?
23
Short Sent.?
100
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.79Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?2.90%Low
Short Interest?1.5M
Days to Cover?1.0
Free Float50.2M
Avg Daily Volume5.8M
Settlement Date2026-05-15
Financial Health
Current Ratio?11.75Strong
Quick Ratio?11.75Strong
Cash Ratio?1.49Strong
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.39CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-43.5%WEAK▾
ROA?
S&P
3
-36.3%WEAK▾
Cash Flow & Enterprise
FCF?$-103785000
Enterprise Value?$98.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist